1	COHORT PROFILE: IMMUNE RESPONSES TO SARS-COV-2 VACCINATION AND INFECTION IN
2	A LONGITUDINAL SAMPLING AMIDST THE COVID-19 PANDEMIC (LONGTONG-SARS2) IN
3	ΜΑΙΑΥSIA
4	
5	Naim Che-Kamaruddin ^{1*} , Jefree Johari ¹ , Hasmawati Yahaya ¹ , Huy C. Nguyen ² , Andrew G.
6	Letizia ² , Robert D. Hontz ² , Sazaly AbuBakar ^{1*}
7	
8	1 Tropical Infectious Diseases Research and Education Centre (TIDREC), Higher Institution
9	Centre of Excellence (HICoE), Universiti Malaya, 50603 Kuala Lumpur, Malaysia
10	² U.S. Naval Medical Research Unit INDO PACIFIC, Singapore
11	
12	Email addresses:
13	Naim Che-Kamaruddin (naimck@um.edu.my)
14	Jefree Johari (jefree@um.edu.my)
15	Hamawati Yahaya (hasmy@um.edu.my)
16	Huy C. Nguyen (huy.c.nguyen3.mil@health.mil)
17	Andrew G. Letizia (andrew.g.letizia.mil@health.mil)
18	Robert D. Hontz (hontzRD@state.gov)
19	Sazaly AbuBakar (sazaly@um.edu.my)
20	*corresponding authors
21	
22	Word count: 5,900
23	
24	
25	
26	
27	

28 ABSTRACT

Purpose: This prospective, longitudinal study aims to evaluate the durability and functionality of SARS-CoV-2 Ancestral strain (Wuhan-Hu-1)-specific immune responses induced by COVID-19 vaccination and natural infection over a 12-month period. This article reviews the study protocol, design, methodology, ongoing data collection, analysis procedures, and demographic characteristics of the cohort enrolled.

34

Participants: Between March 2021 and May 2022, 400 participants were enrolled with a 12month follow-up, concluding in May 2023. Two main groups of participants: (1) serologically SARS-CoV-2-naïve individuals receiving the BNT162b2 primary series vaccination (referred to as VAC) and (2) those who recently recovered from COVID-19 infection within 30 days, regardless of vaccination history (referred to as COV). Additionally, a subset of 45 participants with selected COVID-19 exposure histories provided peripheral blood mononuclear cells (PBMCs) for cross-sectional analysis six months after enrollment.

42

Findings to date: Out of 400 participants, 66.8% (n=267) completed the follow-up. Among them, 52.8% (n=141) were in VAC, and 47.2% (n=126) were in COV. As the study progressed, we acknowledged cross-over between initial groups, leading to restructuring into five revised groups based on sequential exposure events. Sociodemographic factors revealed statistically significant age distribution differences (p=0.001) in both initial and revised groups, with no significant differences observed for sex.

49

50 Future plans: LONGTONG-SARS2 assesses the host-pathogen interactions central to the 51 development of COVID-19 immunity. With enrollment spanning two years of the pandemic, 52 most participants exhibited mixed SARS-CoV-2 exposures—via vaccination and infection— 53 resulting in diverse subgroups of interest. Notably, the inclusion of SARS-CoV-2-naïve, pre-54 exposure serum samples allowed for robust comparator and reduced potential biases. 55 Ongoing analyses will include serology kinetics, memory cells ELISpots, B cells repertoire 56 analysis, cytokine/chemokine profiling, and proteomic pathway to comprehensively 57 examine the immune response against the SARS-CoV-2, thus informing and potentially 58 predicting dynamic longitudinal responses against new more transmissible, immune-evasive 59 SARS-CoV-2 variants.

~	\sim
h	
0	0

61 **Keywords:** cellular immunity, correlate of protection, COVID-19, humoral response, serology

62

63 STRENGTH AND LIMITATIONS OF THIS STUDY

64

LONGTONG-SARS2 is a prospective longitudinal study that comprehensively evaluates the
 SARS-CoV-2 immune response among a diverse group of individuals, stratified based on the
 sequential order of SARS-CoV-2 exposure events, whether from COVID-19 vaccination or
 infection.

69

Pre-vaccination serum samples were collected from serologically SARS-CoV-2 naive
 individuals scheduled to receive the BNT162b2 primary series vaccination during the initial
 mass COVID-19 vaccination phase in Malaysia in early 2021.

73

The longitudinal serum sample collection spanned two years of the COVID-19 pandemic,
from March 2021 to May 2023. This extended duration allows for robust monitoring of the
immune response against SARS-CoV-2 variants in comparison to the ancestral strain.

77

There is a risk of misclassification of some individuals' SARS-CoV-2 exposure status through
serology, as certain sampling timepoints had intervals of three months. Additionally, our
study relies on self-reported data through the *MySejahtera* application (Malaysia's
electronic medical record by the Ministry of Health) for second confirmation, potentially
leading to underdiagnosed and underreported cases of asymptomatic infection.

83

84 **1.0** INTRODUCTION

85

Coronavirus disease 2019 (COVID-19) is an ongoing viral respiratory illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a positive-sense, single-stranded RNA virus. This Risk Group 3 (RG3) virus is phylogenetically related to other Betacoronaviruses which can cause respiratory illnesses in humans, including Severe Acute Respiratory Syndrome Coronavirus 1 (SARS-CoV-1) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [1]. As of 31 December 2023, SARS-CoV-2 has been

92 responsible for more than 773 million COVID-19 cases and more than 7 million deaths 93 globally, with the actual death toll likely to be higher, largely due to the lack of reliable 94 mortality surveillance and tracking systems in many countries and instances where 95 individuals succumbed to COVID-19 before being tested for the virus [2]. Most patients 96 infected with SARS-CoV-2 experienced asymptomatic, mild, or moderate symptoms, and 97 recovered without hospitalization, while a minority developed severe or critical clinical 98 manifestations [3].

99

100 The effectiveness of SARS-CoV-2 vaccines has been well documented [4–6]. However, 101 waning antibody titers which has been documented following three to four months post-102 infection and reports of reduced vaccine efficacy against emerging SARS-CoV-2 variants 103 underscore the need for ongoing assessment of continuous booster immunization [7]. 104 Previous studies suggested that the risk of reinfection is attributed to the waning of 105 neutralizing antibodies (NAb) [4–7]. According to these earlier studies, antibodies are only 106 detected in 60–85% of convalescent individuals, despite detectable levels in 80–95% within 107 two weeks post-symptom onset [8-10]. Considering the serologic kinetics, booster 108 administration increased the serum NAb titer and cross-reactivity against emerging Omicron 109 variants [11]. Although booster immunization has been shown to stimulate antigen-specific 110 antibody production, additional more comprehensive studies are needed to better 111 understand the multifaceted immunological mechanisms that correlate with clinical 112 protection following vaccination and/or natural infection, particularly in the context of the 113 continuing emergence of new immune-invasive SARS-CoV-2 variants [12].

114

115 SARS-CoV-2 exposure from vaccination and/or infection elicits an adaptive immune 116 response, engaging both humoral (primarily antibody-mediated) and cellular immunity, 117 which includes the activation of B and T cells [13]. This dual response establishes long-term 118 memory within the immune system. Upon re-exposure to SARS-CoV-2, the memory B and T 119 cells expand to mount a rapid and targeted defense [6]. Immune memory cells, 120 demonstrated to be more durable, contribute to long-term immunity against variants, even 121 as antibody titers contract [5,6,14]. Evidence of immune imprinting, wherein initial 122 exposures effectively prime B cells but potentially limit the development of novel memory B 123 cells and NAb against emerging SARS-CoV-2 variants, poses a significant challenge to

124 maintaining vaccine efficacy amid the ongoing emergence of novel SARS-CoV-2 variants 125 [15,16]. While the mechanisms of how the immune system recognizes and responds to 126 SARS-CoV-2 variants are still being elucidated, both humoral and cellular immunities play 127 important roles in conferring protection [17]. Therefore, it is imperative to investigate the 128 impact of varied SARS-CoV-2 exposure histories on shaping the immune responses to SARS-129 CoV-2 [16], especially on a regional basis. This is attributed to the variation in immune 130 response across population, with factors such as genetic, environmental, and lifestyle being 131 unique to each region [18]. Moreover, the prevalence of SARS-CoV-2 variants and 132 vaccination strategies in each region can significantly impact viral transmission dynamics. 133 This information becomes crucial for informing public health policies, particularly in the 134 context of emerging highly transmissible variants [19].

135

136 The present study seeks to establish a comprehensive longitudinal prospective cohort 137 comprised of participants exposed to SARS-CoV-2 vaccination and/or infection to define the 138 epidemiological and immunological effects of SARS-CoV-2 in Malaysia. To our knowledge, 139 Malaysia lacks a cohort with a similar extensive design, involving longitudinal sampling up to 140 12 months, spanning from the early phase of the pandemic to the transitioning to an 141 endemic phase. This study fills a crucial gap by providing insights into COVID-19 humoral 142 and cellular immune responses specific to Malaysia. Through investigation of antibody 143 kinetics, T and B cell studies, and adaptive immune responses, our initiative not only 144 contributes valuable data for informing public health strategies but also has the potential to 145 serve as a reference for future research in the region. This article describes the protocol and 146 cohort profile of LONGitudinal sTudy Of immuNe response aGainst SARS-CoV-2 147 (LONGTONG-SARS2).

148

149 **2.0 STUDY OBJECTIVES**

150

The overall aim of **"LONG**itudinal sTudy **O**f immu**N**e response a**G**ainst SARS-CoV-2" (LONGTONG-SARS2) is to evaluate the durability of SARS-CoV-2 specific antibodies, and the functionality of the specific memory B and T cells from a prospective, longitudinal sampling for up to 12 months. The specific objectives include:

155

156 1. To analyze the kinetics of anti-SARS-CoV-2 antibodies (IgM, IgA, IgG, NAb) response for up to 12 months by ELISA assays for each group. 157 158 2. To assess the functional immune memory response of SARS-CoV-2-specific memory 159 B and T cells by ELISpot assays. 160 3. To characterize the interaction of cytokines and immune cells through bead-based 161 analytes. 162 4. To profile the serum protein pathways before and after SARS-CoV-2 vaccination or 163 infection from bottom-up proteomic analysis. 164 5. To identify the distribution and incidence of SARS-CoV-2 exposures by duration since 165 the primary series of vaccination doses, frequency of infection(s), and date of 166 exposure in the study population by descriptive analysis. 167 6. To evaluate the association of antibody distribution and baseline demographic, 168 comorbidities, as well as symptoms/adverse effects following immunization (AEFI) 169 observed during enrollment, subsequent to SARS-CoV-2 exposures via vaccination or

infection by generalized estimating equation (GEE) analysis.

- 170 171
- 172 3.0 COHORT DESCRIPTION
- 173
- 174 **3.1** Terminology definitions:

175 The terminology used in the present study are:

"Vaccination" - Participants were classified as vaccinated if they received COVID-19
 vaccination regardless of number of doses. Proof of vaccination is a mandatory
 requirement for inclusion in any vaccination data collection within the scope of the
 present study. Participants who received the primary vaccination series were
 categorized as fully vaccinated two weeks after the last dose, while those receiving
 additional vaccine doses after the primary series were classified as boosted.

"Infection" - Participants were classified as infected if they presented proof of a positive case through PCR or rapid test results in either their records (as well as from the electronic medical record by Ministry of Health, *MySejahtera* application) OR demonstrated at least a 4-fold increase in IgG or IgM levels from the consecutive sampling timepoints. Individuals exhibiting a 4-fold increase in IgG or IgM without

documented proof (due to the absence of symptoms) were considered to haveasymptomatic infection.

- "Reinfection" Reinfection status for participants was documented if multiple
 occurrences of COVID-19 infections were recorded in the electronic medical record
 OR if there was at least a four-fold increase in IgG or IgM levels from the consecutive
 sampling timepoints even without the records.
- Breakthrough infection (BTI)" The BTI status for participants was documented if
 the date of infection occurred after Day-15 of the second dose of COVID-19
 vaccination, indicating completion of the vaccination regimen.
- "Exposure" -Vaccination, infection, reinfection, and BTI were considered as
 exposure in the present study.
- "Cross-exposure" Participants were defined to have cross-exposure if they
 experienced both COVID-19 vaccination and infection, irrespective of the sequence
 of exposure.
- 201

202 3.2 Study design

203

The study design involved a longitudinal study with enrollment of two groups of different SARS-CoV-2 exposures, which are (1) the serologically SARS-CoV-2-naïve individuals who were scheduled to receive primary series vaccination with BNT162b2 (VAC) and (2) post-COVID-19 infected group (COV) regardless of their vaccination histories. The participants were informed beforehand about all aspects of the study, and individuals who fulfilled the inclusion criteria were given an informed consent form and a case report form (CRF) adhering ethical approval (MREC-UMMC SID: 2021226-9886).

211

212 The inclusion criteria are as follows:

213

214 🛛 Seven years or older, AND

- 215 I Healthy individuals without active SARS-CoV-2 infection at the time of enrollment,
- 216 AND

217	?	Healthy individuals without immunosuppressive conditions such as HIV and cancer				
218		patients, AND EITHER				
219	?	Scheduled for the primary series vaccination with BNT162b2 with a negative baseline				
220		SARS-CoV-2 anti-S1 IgG serology, corresponding to no previous SARS-CoV-2 exposure				
221		(to be enrolled in the VAC group), OR				
222	?	Had been infected with SARS-CoV-2 within 30 days and able to provide proof of				
223		infection either from rapid test kit or PCR (to be enrolled in the COV group),				
224	?	AND agreed to give voluntary informed consent to participate in the study				
225						
226	The ex	clusion criteria are as follows:				
227	?	Individuals with immunosuppressive conditions such as HIV and cancer patients, OR				
228	?	Individuals unable to attend the scheduled follow-up appointments				
229						
230	Epide	miological data obtained in the CRF include:				
231	?	Demographics - Age, gender, body mass index (BMI), medical comorbidities				
232	?	Exposure history - Date of vaccinations, COVID-19 vaccine types, date of COVID-19				
233		infections				
234	?	Clinical manifestations experienced - Adverse effect following immunization (AEFI)				
235		and symptoms following COVID-19 infection				
236						
237	3.3	Sample size estimation				
238						
239	A sample size of 400 participants (N=400) was targeted to achieve statistical power as					
240	calculated using GLIMMPSE software (https://glimmpse.samplesizeshop.org/), taking into					
241	consideration the repeated measures and longitudinal design [9,10,20].					
242						
243	In GLIMMPSE, the Hotelling-Lawley Trace test was utilized with a conservative Type 1 error					
244	rate of 0.5, with the total sample size for the analysis being 66 participants. An estimated					
245	30% attrition rate was used, and an adjusted estimation formula of 66 / (1-0.3) was applied					
246	to accommodate this attrition, resulting in a minimum total sample size requirement of 95					
247	partic	ipants. For the present study, the total of 400 participants were chosen to increase				
248	the statistical power and accommodate potential loss of follow-up participation.					

249

250 3.4 Enrollment

251

252 Following all required ethics approvals, eligible participants were enrolled. Enrollment 253 material (i.e., advertisements, posters, and flyers) were posted on social and printed media. 254 The target study participants primarily comprised of individuals from the public residing in 255 the greater Kuala Lumpur area (Supplemental Figure 1). Due to the restrictions imposed by 256 the nationwide MCO, we utilized both convenience sampling, selecting participants based 257 on their accessibility and proximity to the study site, and snowball sampling, where existing 258 participants referred others for the study. Participant enrollment commenced in March 259 2021, coinciding with the initial phase of COVID-19 vaccine distribution in Malaysia. Initially, 260 potential participants were provided with comprehensive information on the study, which 261 included the study purpose, blood collection procedures, and the prerequisite follow-ups. 262 Consented participants completed informed consent. Visit schedules for sample collection 263 were sent via an electronic appointment card. Collected blood samples were transported on 264 ice to the laboratory, where the serum samples were processed and stored in -80°C freezer 265 until needed for laboratory analysis.

266

267 Enrollment closed at the end of July 2022, and the blood sampling ended at the end of May268 2023.

269

270 3.5 Blood sample collection

271

272 Longitudinal blood sampling for up to 12 months was required for all participants following 273 the timepoints described in Figure 1. Participants in the VAC group were scheduled for a 274 total of 9 sampling timepoints, spanning from pre-vaccination or baseline to Day-360 days 275 post the first vaccine dose. Meanwhile, the COV group had 7 scheduled timepoints, initiated 276 from the first month of infection. Notably, sample collection timepoints for both groups 277 coincided on Day-14 post first exposure, Day-90, Day-180, Day-270, and Day-360 post-278 vaccination/infection. A sampling window of ± 7 days was applied to the designated 279 sampling timepoints for participants' flexibility and availability. One (5 mL) tube with a 280 separator gel and clot activator for whole blood samples was drawn for each timepoint.

281 Blood samples were processed with serum extracted from each sample for the serology

282 testing.

283

284 A cross-sectional collection of Peripheral Blood Mononuclear Cells (PBMCs) was conducted 285 from Day-180 to Day-360 to assess the cellular immune response. Among the 400 286 participants, 45 were randomly selected and consented for PBMCs collection. To establish a 287 control group for cellular immune response analysis, an additional 5 participants who had 288 no COVID-19 vaccination documented in a local electronic record, MySejahtera and were 289 not previously involved in the LONGTONG-SARS2 serology study, were included. Details of 290 the vaccination types and the frequency of SARS-CoV-2 infection were collected to form 291 groups based on these parameters (details are shown in Supplemental Table 3). For the 292 PBMCs collection, four (8 mL) lymphocyte isolation tubes (BD Vacutainer[®] CPT[™] 293 Mononuclear Cell Preparation Tube) were used. The PBMCs were isolated and assessed for 294 cell count estimation and viability using BioRad TC20[™] Cell Counter.

295

296 297

6 3.6 Participant and public involvement

LABORATORY INVESTIGATIONS

Participants or the public were not involved in the design, or conduct, or reporting, ordissemination plans of our study.

- 300
- 301

4.0

302

303 There are five major components of laboratory analysis: i) serology monitoring, ii) B- and T-304 memory cell functionality, iii) B lymphocyte population counting, iv) cytokine profiling, and 305 v) proteomic profiling (Figure 2). Briefly, the serology monitoring involves the longitudinal 306 quantification for specific antibodies against SARS-CoV-2. The assessment of B- and T-307 memory cells functionality seeks to understand how well the immune memory responds 308 upon re-exposure to SARS-CoV-2 antigens. B lymphocyte population counting intends to 309 elucidate the heterogeneity in B cells population following the re-exposure, while cytokine 310 profiling involves identifying key signaling molecules that are upregulated or downregulated 311 as part of the immune response. Additionally, proteomic profiling provides a broader view 312 of protein expression patterns during the immune response. Profiling the various arms of

the immune system will help establish a comprehensive analysis for a holistic understandingof how the immune system responds against SARS-CoV-2.

315

316 4.1 Serology monitoring

317

Serological testing of serum samples employs four different commercially available anti-318 319 SARS-CoV-2 ELISA kits targeting either receptor-binding-domain (RBD) or spike (S) protein. 320 The kits used in the present study include detection of IgM (WANTAI, Beijing Wantai 321 Biological Pharmacy Ent.), IgA, IgG, and NAb (EUROIMMUN, Lubeck, Germany). Serologic 322 testing was conducted at every time point, following the manufacturer's protocols. The 323 threshold for positivity of RBD-specific IgM is defined at an optical density of 0.105 OD at a 324 wavelength of 450 nm (OD₄₅₀), with a reference at 650 nm (OD₆₅₀). For S1-specific IgA, 325 semiguantitative results are derived by calculating the OD ratio using the samples and a 326 provided standard. A positivity cut-off value of 1.1 OD ratio is established to interpret 327 results. For S1-specific IgG, quantitative determination of binding antibody units (BAU/mL) is 328 obtained using the standards provided by the manufacturer with a positivity cut-off value of 329 35.2 BAU/mL. Serum NAb activity against S1/RBD-Wuhan-Hu-1 SARS-CoV-2 (Wuhan 330 wildtype) is measured in a surrogate Virus neutralization Test (sVNT) based on competitive 331 ELISA. According to the manufacturer sheets, the sensitivity of these commercial ELISA kits 332 ranges from 86.1% to 96.9%, and the specificity ranges from 98.3% to 99.8%.

333

334 **4.2** *Memory cells functionality through ELISpot*

335

336 The functionality of memory B and T cells is analyzed using PBMCs stimulated against SARS-337 CoV-2 antigens in vitro. Commercial ELISpot assays (Mabtech, Sweden) quantify the 338 production of RBD-specific IgG in memory B cells. The assays assess the production of cytokines, particularly interferon-gamma (IFN-y) in memory T cells. Briefly. 2 x 10⁵ cells are 339 340 incubated with SARS-CoV-2 peptides for 24 to 72 hours, and spot development is performed 341 according to the manufacturer's protocol. Unstimulated controls for each sample function 342 as the internal reference, enabling a comparative analysis of stimulated changes using the 343 individual's baseline as a reference point. Spots are counted using an ImmunoSpot® analyzer 344 and converted into spots forming unit per million cells (SFU/mL) for standardization. The

345 collected data is analyzed to determine the frequency of cytokine-producing memory T cells

and IgG-secreting memory B cells, as previously described [6].

347

348 **4.3 B** lymphocytes subsets response through flow-cytometric analyses

349

350 PBMCs were analyzed using flow cytometry to discern the frequency of distinct B cell 351 subpopulations and their potential correlation with cell functionality. Flow cytometric 352 analyses were designed in the present study to characterize the B cell response include cell 353 viability (7-AAD), mature B cell lineage (CD19+ CD20+), transitional B cell (CD38 dim/-354 CD24+), antibody-secreting cell (CD38+ CD24- CD27+ CD20-), CD27 and IgD for atypical 355 memory B cells, memory B cells, innate-like memory B cells, naïve B cells. Spike and RBD-356 specific SARS-CoV-2 markers, including BB515 Streptavidin BV421 Streptavidin for double 357 spike+, BB515 Streptavidin BV421 Streptavidin for double spike+ with spike RBD+, and IgM 358 with IgG to distinguish the primary and secondary response in the stimulated samples. 359 Previous literature on cellular immunity response against SARS-CoV-2 were referred for the 360 cells subset as previously describe [5,21]. A BD FASCLyric[™] cell analyzer was be used to 361 characterize the samples.

362

363 4.4 Cytokine profiling

364

365 In the subset of 45 selected participants, including the 5 unvaccinated control participants, 366 cytokine levels from the supernatant of cells suspension are assessed using the Bio-Plex 367 multiplex magnetic bead-based human cytokine assay (Bio-Rad, CA, USA) with the 27-Plex 368 Screening Panel (#M500KCAF0Y). The Bio-Plex 200 Reader measures median fluorescence 369 intensities, and each sample undergoes triplicate analysis. Data acquisition and analysis are 370 performed using Bio-Plex Manager Software. Standard curves for each cytokine are 371 established using the provided manufacturer's standards according to manufacturer's 372 instruction and as described previously [22].

373

In this study, we focused on 27 unique cytokines which involves in inflammatory responses and initiate cellular immune signals: eotaxin, fibroblast growth factor (FGF), granulocyte colony-stimulating factor (G-CSF), interferon- γ (IFN- γ), IL-1 β , interleukin 1 receptor

antagonist (IL-1RA), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17A, interferon- γ -inducible protein (IP-10), monocyte chemoattractant protein-1 (MCP-1, MCAF), macrophage inflammatory protein-1 α (MIP-1 α), MIP-1 β , platelet-derived growth factor-BB, regulated upon activation, normal T-cell expressed and presumably secreted (RANTES), tumor necrosis factor- α (TNF- α), and vascular endothelial growth factor-A (VEGF).

382

383 4.5 Proteome Profiling

384

385 Longitudinal serum samples were used to study the host proteomic response against COVID-386 19 vaccination and/or infection. During the protein preparation, high abundance proteins 387 were depleted by a commercial kit. High Select[™] Depletion Spin Columns (Thermo Scientific, 388 USA), and protein digestion was performed using EasyPep[™] MS Sample Prep Kits (Thermo 389 Scientific, USA). Protein identification and quantification are performed using the 390 untargeted Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Q-TOF (Agilent 391 Technologies 6520, USA) system. Samples were identified using data-independent 392 acquisition mode. Spectra from each fraction are explored in the protein database, and the 393 results are imported to generate a library to identify differentially expressed proteins (DEPs) 394 that significantly vary between samples. The functional significance of DEPs is explored 395 using bioinformatics tools, including Gene Ontology (GO) and KEGG pathway analysis 396 following protocols of available study [23].

- 397
- 000

398 **4.6** Data analysis and modeling plan

399

400 At the time of study conceptualization during the early phase of the pandemic, the initial 401 objective was to compare the immune response between participants receiving only the 402 BNT162b2 vaccine with no infection to those post-COVID-19 infection without vaccination, 403 focusing on (1) measurement of serum-neutralizing antibodies, IgG, IgA, IgM response 404 against SARS-CoV-2 for up to 12 months and (2) evaluation of the long term-memory B and 405 T lymphocyte-mediated immune response. The inclusion of only BNT16b2 vaccine in the 406 present study was informed by its predominant primary series vaccine used in Malaysia. 407 Throughout the pandemic, the study analysis plans had to undergo continuous adjustments 408 and adaptation to account for group overlap due to varying accumulation of SARS-CoV-2

409 exposures outside of the control of the study investigators, such as the implementation of 410 the government's vaccine rollout plan and the emergence of new more transmissible and 411 immune-evasive variants that cause breakthrough infections. To accommodate these 412 limitations, additional data on COVID-19 vaccination, booster doses, and COVID-19 infection 413 histories were requested from the participants at the end of their last sampling timepoints. 414 These data were collected from a local government-sponsored and mandated electronic 415 record, the MySejahtera application available on all participants' mobile devices to limit 416 recall bias. The additional data were utilized to determine cross-exposure in participants, 417 specifically examining the immune response against SARS-CoV-2 induced by either 418 vaccination alone, infection alone, or a combination of both. Only participants who provided 419 proof of vaccination certificate and diagnostic results from rapid test kits or PCR were 420 included in the final analysis. Additionally, 4-fold increment increases in anti-SARS-CoV-2 S1 421 IgG over consecutive sampling timepoints (outside of the vaccination period) were 422 monitored to account for asymptomatic infections. Participants in the VAC group with 423 COVID-19 infection are grouped based on breakthrough infection (BTI) status. Plans to 424 analyze these results are in progress and will be reported in future publications.

425

426 A complete-case analysis approach was chosen, wherein only participants who completed 427 the entire follow-up period for blood sampling and provided fully completed Case Report 428 Forms (CRFs) were included in the analysis. The assumption was that the excluded 429 participants were represented randomly, indicating that the missing data was categorized as 430 Missing Completely at Random (MCAR) data [24] and therefore the excluded data will not 431 affect the statistical analyses.

432

433 Descriptive statistics were employed to summarize the characteristics of study participants 434 and relevant variables, providing an overview of data distribution and cohort demographics. 435 Age groups were categorized according to common life stages, which are group \leq 30 years old (teenagers and young adults), 31-40 years old (adults), > 40 years old (late adults to 436 437 seniors/elderly), respectively. Logistic regression will be used to assess the association 438 between categorical outcomes (e.g., symptoms/AEFI severity, antibody waning status) and 439 predictor variables (e.g., vaccination types, frequency of infection), while generalized 440 estimating equation (GEE) models will be used to account for longitudinal data with

441 repeated measurements, enabling the examination of changes in immune response markers 442 and BTIs/reinfections over time. Correlation tests explore relationships between continuous 443 variables, revealing the strength and direction of factor associations. Additionally, survival 444 analysis is employed for time-to-breakthrough infection/reinfection, and cluster analysis 445 identifies distinct participant subgroups based on immune response profiles or other 446 characteristics such as the SARS-CoV-2 vaccination types and infection frequency. The 447 analyses are performed using established statistical software (e.g., R, SPSS, GraphPad 448 Prism).

449

450 **5.0 FINDINGS TO DATE**

451

452 Initially 184 SARS-CoV-2 naïve, SARS-CoV-2 anti-S1 lgG seronegative participants were 453 enrolled into the VAC group in March 2021 and April 2021 before their scheduled BNT162b2 454 vaccination (Supplemental Figure 2). This was made possible by our university hospital's 455 designation as a vaccination distribution center, allowing us to enroll study participants even 456 during MCOs. Starting in May 2021, however, there was a decrease in the number of SARS-457 CoV-2 naïve participants due to the Malaysian government's mass vaccination campaign. 458 This decline presented challenges in meeting our initial target of 200 participants for the 459 VAC group.

460

461 In contrast, the enrollment for the COV group encountered a slowdown in the initial phase 462 of the study, leading to an extension. This delay was prompted by unexpected restrictions 463 imposed during the MCO implemented by the Malaysian government between March 2020 464 and December 2021 including limitations on gathering, mobility, and international travel, 465 along with the closure of government, business, and educational institutions to prevent the 466 spread of SARS-CoV-2. However, enrollment for the COV group experienced a significant 467 increase in March 2022, coinciding with the emergence of the Omicron variant. Despite the challenges, we successfully enrolled 216 COV group participants with post-COVID-19 natural 468 469 infection. An additional 16 participants were included to compensate for the participation 470 numbers in the VAC group.

471

The decrease in retention rate started at Day-180 of sample collection (Supplemental Table 1). Through our observations and interactions with participants, the primary reason for study withdrawal was the resumption of their usual daily responsibilities during the transition from the pandemic to the endemic phase. Consequently, shifting priorities among participants led to a diminished interest in continuing their participation in the study. By the final follow-up on Day-360, the total retention rate throughout all sampling timepoints was 70% (n=280/400) which providing a sample at every single sampling timepoint.

479

480 5.1 Enrollment strategies

481

Given the ongoing COVID-19 pandemic during the study, we informed the participants of their serology test results to make them aware of their status against SARS-CoV-2. By sharing serology results, participants were likely motivated to remain engaged in the study, as they recognized the importance of continuous surveillance.

486

487 In addition, we also implemented a mobile follow-up service to enhance participant 488 engagement especially during the MCOs. The research team contacted participants to 489 schedule home visits for sample collection to ensure a higher retention rate. Overall, from 490 our observation, keeping participants informed about the study's progress, providing timely 491 updates, and addressing their concerns were the key factors in building strong trusting 492 relationships and rapport with the participants. These strategies strengthened our 493 enrollment and retention efforts, fostering an engaged cohort. This approach has not only 494 empowered individuals from various backgrounds to participate actively but also 495 contributed to the overall success and validity of our research study.

- 496
- 497 **5.2**
- 498

A limitation within our study design arises from the early conceptualization during the initial stages of the pandemic, resulting in cross-exposure between the initial study groups. Consequently, the distinction between breakthrough infections in the vaccination-only (VAC) group and vaccinations in the infection-only (COV) group was not effectively addressed. This limitation hindered the ability to exclusively isolate the immune response

Modification of the study designs

from either VAC or COV throughout the entire blood sampling period. Furthermore, there is a possibility of underreported data on previous infection history due to the potential occurrence of asymptomatic infections. Another important limitation is that we only gathered data on symptoms and adverse events following immunization (AEFI) during the enrollment phase, without continuing to track during the breakthrough infections and reinfections in the later stages of the study.

510

511 We acknowledged the potential confounding effects from individual behaviors and 512 personality traits when assessing the influence of vaccination timing on SARS-CoV-2 513 breakthrough infection risk. Variability in risk perception and health-related behaviors 514 between early vaccine recipients and those delaying vaccination, alongside socioeconomic 515 disparities and differential access to healthcare, present significant challenges in analysis. 516 Therefore, we will perform multivariate analyses and sensitivity analyses to assess the 517 robustness of findings across different exposures, while using regression modeling control 518 for confounding variables.

519

520 **5.3** Cross-exposure of SARS-CoV-2 vaccination and infection from initial groupings

521 522 With the emergence of breakthrough infections and reinfections, we reconsidered the initial 523 stratification of VAC and COV groups due to cross-exposure between the 2 groups. 524 Supplemental Figure 3 shows an overlapped graph depicting the sampling period of LONGTONG-SARS2 study and the national SARS-CoV-2 variants genomic surveillance data in 525 526 Malaysia. We expected significant hybrid immunity, arising from both natural infections 527 followed by vaccination and vice-versa, to be present in both participant groups amidst the 528 emergence of highly transmissible variants and the high number of COVID-19 cases in 529 combination with mass country-wide vaccination campaigns (Supplemental Figure 3, 530 Supplemental Figure 4, Supplemental Table 2).

531

532 During the peak of Delta and Omicron circulation, when these variants constituted 75% of 533 the COVID-19 cases in Malaysia (Hodcroft, 2023), we enrolled 67 and 222 participants, 534 respectively. Those participants were likely infected with those variants based on the 535 dominant circulating variants during the enrollment (Supplemental Figure 4). However, the

present study did not involve sequencing respiratory samples. Instead, we inferred the participants' likely infection variant based on contemporary national genomic sequencing data [25].

539

540 During the peak of the Delta variant, 16.8% of all participants (n=67/400) were identified, 541 with 23.6% (n=51/216) from the COV group and 8.7% (n=16/184) from the VAC group. 542 Similarly, during the peak of the Omicron variant, 55.5% of all participants (n=222/400), with 543 67.1% (n=145/216) in the COV group and 41.8% (n=77/184) in the VAC group.

544

545 Cross-exposure of SARS-CoV-2 vaccination and infection was observed from the initially 546 stratified participants throughout the 12-month sampling period in the present study 547 (Supplemental Table 2). Almost two-thirds (68.8%) of all study participants (n=275/400) 548 encountered breakthrough infections. Notably, within the VAC group, more than half 549 (53.3%) experienced breakthrough infections (n=98/184). Furthermore, almost every 550 participant (98.6%) in the COV group (n=213/216) had received a full primary series COVID-551 19 vaccination due to mass vaccination campaigns implemented by the Malaysian 552 government to ensure a high vaccination rate. Detailed demographic data of this subset 553 population can be referred to the Table 1 and Table 2.

554

555 **5.4** Participants' demographics and study groups restructuring

556

557 Of the 400 participants, 70% (n=280) completed the blood sampling follow-ups 558 (Supplemental Table 1). Among them, 66.8% (n=267) completed the follow-ups and CRF. 559 These 267 were included for the final analyses.

560

Of the 267 participants, 52.8% (n=141) are from the VAC group, while the remaining 47.2% (n=126) belonged to the COV group (Table 1). Demographic characteristics revealed a balanced sex distribution, with 39.3% male and 60.7% female participants (p=0.253). Age distribution showcased a significant difference across age groups (p=0.001), with 20.2%, 47.6%, and 32.2% of participants falling into age groups \leq 30 years old, 31-40 years old, and > 41 years old, respectively. Median age of participants was 36 years old (\bar{x} =37, IQR=9 to 73).

568

569 Table 1. Distribution of sociodemographic factors by sex and age groups according to initial participant

570 grouping, VAC versus COV. Abbreviations: VAC = SARS-CoV-2-naïve prior to scheduled BNT162b2 primary

	VAC	COV	Total	X ² Stat (df)	p-value
Sex					
Male	60 (42.5%)	45 (35.7%)	105 (39.3%)		
Female	81 (57.4%)	81 (64.3%)	162 (60.7%)	1.30 (1)	0.253
Age group					
≤ 30	17 (12.1%)	37 (29.4%)	54 (20.2%)		
31-40	68 (48.2%)	59 (46.8%)	127 (47.6%)	15.11 (2)	0.001
> 40	56 (39.7%)	30 (23.8%)	86 (32.2%)		
Total	141 (52.8%)	126 (47.2%)	267 (100%)		

571 series vaccination; COV = recently recovered from COVID-19 infection.

572

573 In the revised study participant grouping, our study delineated five distinct subgroups. 574 These included "E/VAC(BNT)/COVID-ve", "E/VAC(BNT)/COVID+ve", "VAC(BNT)/COVID+ve/E", "VAC(any)/COVID+ve/E", and "COVID+ve/E/VAC(any)" (Figure 3). 575 Where the acronym is defined as "E" is Enrolled; "VAC(***)" is vaccination type either 576 577 BNT162b2 or any vaccinations; "COVID*ve" is the status of COVID-19 infection either 578 positive or negative. Forward slashes in the revised group names separate distinct events in 579 chronological order.

580

In detail, the five distinct groups within our study cohort, each defined by their vaccination
history and COVID-19 infection status:

1. "E/VAC(BNT)/COVID-ve" = this group comprised participants who were enrolled,
 received the primary series of BNT162b2 vaccination, and did not experience a
 breakthrough COVID-19 infection.

586 2. "E/VAC(BNT)/COVID+ve" = this group comprised participants who were enrolled,
587 received the primary series of BNT162b2 vaccination, and had documented
588 breakthrough COVID-19 infection.

3. "VAC(BNT)/COVID+ve/E" = this group comprised participants who received the primary series of BNT162b2 vaccination prior to enrollment in the study, later had documented breakthrough COVID-19 infection, and subsequently enrolled the study.
4. "VAC(any)/COVID+ve/E" = this group comprised participants vaccinated with a primary series of COVID-19 vaccination (other than BNT162b2), later had documented breakthrough COVID-19 infection, and subsequently enrolled in the study.

596 5. "COVID+ve/E/VAC(any)" = this group comprised participants who had documented
597 COVID-19 infection prior to study enrollment and subsequently received a primary
598 series of COVID-19 vaccination (other than BNT162b2).

599

The results of the Chi-square test indicate that the distribution of sex and age groups in the revised study group is comparable to that in the initial study groups (Table 2). Median age of participants in the revised group was 36 years old (\bar{x} =38, IQR=15 to 65). There were no significant differences in sex (p-value=0.324); however, a significant difference was observed among age groups (p-value=0.001).

605

606 **Table 2.** Distribution of sociodemographic factors of sex and age group by revised study group.

	E/VAC(BNT)/COVID-ve	E/VAC(BNT)/COVID+ve	VAC(BNT)/COVID+ve/E	VAC(any)/COVID+ve/E	COVID+ve/E/VAC(any)	Total	X ² Stat (df)	p- value
Sex								
Male	27 (26%)	30 (29%)	22 (21%)	14 (13%)	12 (11%)	105 (39%)	4.66 (4)	0.324
Female	25 (15%)	55 (34%)	40 (25%)	25 (15%)	17 (11%)	162 (61%)		
Age								
group	7 (120()	10 (10%)	10 (220()	19 (229()	7 (120/)	E4 (200()		
21 40	7 (13%)	10 (19%)	12 (2276)	16 (33%)	7 (1376)	107 (20%)	20.04(0)	0.001
31-40	24 (19%)	42 (33%)	35 (28%)	15 (12%)	11 (9%)	127 (48%)	26.94 (8)	0.001
>40	21 (24%)	33 (38%)	15 (17%)	6 (7%)	11 (13%)	86 (32%)		
Total	52 (20%)	85 (32%)	62 (23%)	39 (15%)	29 (11%)	267 (100%)		

607

Additionally, for the cross-sectional PBMCs collection, we will conduct a comparative analysis of cellular immune responses among individuals in both homologous and heterologous vaccination groups, further stratifying them based on breakthrough infection occurrence (Supplemental Table 3). The cellular responses within these vaccinated groups will be compared with those of an unvaccinated control group.

613

614 6.0 FUTURE DIRECTIONS

615

616 Studies are planned or ongoing examining the kinetics of antibody production post-SARS-617 CoV-2 vaccination and infection. Preliminary analysis indicates variations among the revised 618 study groups, prompting further investigation into the factors influencing the rate of decline 619 and persistence of antibody levels over time in response to breakthrough infection and/or 620 reinfection. Furthermore, in our exploration of the potential correlates of protection, we will 621 examine the specific antibody, memory B cell, and proteomic response that best correlate 622 with durability and functionality of immune response against SARS-CoV-2. These analyses 623 are pending. Additional investigations will examine how previous exposures to SARS-CoV-2, 624 whether through vaccination or infection, impact adaptive immune responses during 625 subsequent exposures to elucidate the role of memory B cells and memory T cells in 626 sustaining long-term immunity. Taken together, the cohort from the present study will be 627 leveraged to delve into a focused exploration of the heterogeneity of SARS-CoV-2 immune 628 responses arising from diverse vaccination regimens and antigen exposures.

629

630

7.0 ETHICS, COLLABORATION, AND DISSEMINATION

631

632 This study is strictly adhered to the ethical principles outlined in the World Medical 633 Association Declaration of Helsinki. Ethical approval was obtained from Universiti Malaya 634 Medical Centre (MREC-UMMC SID: 2021226-9886), ensuring compliance with all relevant 635 federal regulations governing the protection of human subjects. All study personnel hold 636 certifications in Good Clinical Practice. The study is supported by the U.S. Naval Medical 637 Research Unit INDO PACIFIC (NAMRU INDO PACIFIC) and will adhere to the NAMRU INDO 638 PACIFIC regulations for publication in open-access journals and data management.

639

640 The research team welcomes opportunities for potential research collaborations. The data 641 from this study can be obtained upon request from the corresponding author, SAB. 642 Permission to access data and analytical files is contingent upon approval from the relevant 643 research ethics committees and the data custodian. The LONGTONG-SARS2 biological 644 materials and data custodians are the Tropical Infectious Diseases Research and Education 645 Centre (TIDREC) and the U.S. Naval Medical Research Unit INDO PACIFIC (NAMRU INDO 646 PACIFIC).

647

Key study findings will be disseminated through various channels to ensure widespread and transparent communication. Results will be published in journals for the scientific community. Furthermore, the findings will be presented at national and international conferences, facilitating knowledge exchange and fostering collaboration with researchers worldwide. Notably, the study team is committed to communicating the results to the study population. By ensuring direct and accessible communication, participants will be informed on the progress and outcomes of the present study in which they have actively participated.

655

656 Funding

The study was supported by funds from the U.S. Joint Program Executive Office under the 2020-2021 Coronavirus Aid, Relief, and Economic Security (CARES) Act.

659

660 Acknowledgment

661 We acknowledge the dedication and commitment of the voluntary study participants 662 without whom this project would not have been possible.

663

664 Authors' contribution

SAB had full access to all the study data and takes responsibility for the integrity of the data
and the accuracy of the data analysis. Study concept and design: SAB, JJ, RH, NCK.
Participant enrollment and data collection: NCK, JJ. Sample processing: NCK. Laboratory
work: NCK. Data analysis and interpretation: NCK. Original drafting of manuscript: NCK.
Editing and revision of manuscript: NCK, JJ, HY, HN, AL, RH, SAB. Study coordination: SAB, JJ,
HY, HN, AL, RH, NCK. All authors read and approved the final article.

671

Disclaimer. The views expressed in this article are those of the authors and should not be construed to reflect the official policy or represent the positions of the U.S. Department of the Navy, Department of Defense, nor the United States Government. LT Huy C. Nguyen, MC, USN NAMRU-IP; LCDR Robert D. Hontz, MSC, NAMRU-IP; CAPT Andrew G. Letizia, MC, USN NAMRU-IP are military service members. This work was prepared as part of their official duties. Title 17 U.S.C. 105 provides that `copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. 101 defines a U.S.

- 679 Government work as work prepared by a military service member or employee of the U.S.
- 680 Government as part of that person's official duties.
- 681

682 Competing interests

- 683 The authors declare that there is no competing interest.
- 684
- 685 References

686

- Kaufer AM, Theis T, Lau KA, et al. Laboratory biosafety measures involving SARS-CoV and the classification as a Risk Group 3 biological agent. Pathology. 2020;52: 790.
 doi:10.1016/J.PATHOL.2020.09.006
- 690 2. World Health Organization. WHO COVID-19 dashboard. 2024 [cited 20 Mar 2024].
 691 Available: https://data.who.int/dashboards/covid19/cases?n=c
- Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, et al. Case fatality rate of COVID19: a systematic review and meta-analysis. J Prev Med Hyg. 2021;62: E311–E320.
 doi:10.15167/2421-4248/JPMH2021.62.2.1627
- 695 4. Dugan HL, Stamper CT, Li L, et al. Profiling B cell immunodominance after SARS-CoV-2
 696 infection reveals antibody evolution to non-neutralizing viral targets. Immunity.
 697 2021;54: 1290-1303.e7. doi:10.1016/J.IMMUNI.2021.05.001
- 5. Jeffery-Smith A, Burton AR, Lens S, et al. SARS-CoV-2-specific memory B cells can
 persist in the elderly who have lost detectable neutralizing antibodies. J Clin Invest.
 2022;132. doi:10.1172/JCl152042
- 7016.Liu Y, Zeng Q, Deng C, et al. Robust induction of B cell and T cell responses by a third702dose of inactivated SARS-CoV-2 vaccine. Cell Discov. 2022;8. doi:10.1038/S41421-703022-00373-7
- 704 7. Ortega N, Ribes M, Vidal M, et al. Seven-month kinetics of SARS-CoV-2 antibodies and
 705 role of pre-existing antibodies to human coronaviruses. Nat Commun. 2021;12.
 706 doi:10.1038/S41467-021-24979-9
- 8. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of
 neutralizing antibody responses in the three months following SARS-CoV-2 infection
 in humans. Nat Microbiol. 2020;5: 1598–1607. doi:10.1038/S41564-020-00813-8
- 9. Gerhards C, Thiaucourt M, Kittel M, et al. Longitudinal assessment of anti-SARS-CoV-2
 711 antibody dynamics and clinical features following convalescence from a COVID-19
 712 infection. Int J Infect Dis. 2021;107: 221–227. doi:10.1016/J.IJID.2021.04.080
- Guiomar R, Santos AJ, Melo AM, et al. Monitoring of SARS-CoV-2 Specific Antibodies
 after Vaccination. Vaccines. 2022;10. doi:10.3390/VACCINES10020154
- Seki Y, Yoshihara Y, Nojima K, et al. Safety and immunogenicity of the Pfizer/BioNTech
 SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron
 variants. Med. 2022;3: 406-421.e4. doi:10.1016/J.MEDJ.2022.04.013
- 71812.Stephens DS, McElrath MJ. COVID-19 and the Path to Immunity. JAMA. 2020;324:7191279–1281. doi:10.1001/JAMA.2020.16656
- 72013.Castro-Dopico X, Ols S, Loré K, et al. Immunity to SARS-CoV-2 induced by infection or721vaccination. J Intern Med. 2022;291: 32–50. doi:10.1111/JOIM.13372

- Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T
 cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185:
 847-859.e11. doi:10.1016/J.CELL.2022.01.015
- 15. Evans JP, Liu S-L. Challenges and Prospects in Developing Future SARS-CoV-2
 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing
 Antibodies. J Immunol. 2023;211: 1459–1467. doi:10.4049/JIMMUNOL.2300315
- 16. Wang Q, Guo Y, Tam AR, et al. Deep immunological imprinting due to the ancestral
 spike in the current bivalent COVID-19 vaccine. Cell Rep Med. 2023;4.
 doi:10.1016/J.XCRM.2023.101258
- 731 17. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, et al. SARS-CoV-2 infection: The
 732 role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54: 62.
 733 doi:10.1016/J.CYTOGFR.2020.06.001
- 73418.Virolainen SJ, VonHandorf A, Viel KCMF, et al. Gene-environment interactions and735their impact on human health. Genes Immun. 2023;24: 1–11. doi:10.1038/S41435-736022-00192-6
- MacIntyre CR, Costantino V, Trent M. Modelling of COVID-19 vaccination strategies
 and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia.
 Vaccine. 2022;40: 2506–2513. doi:10.1016/J.VACCINE.2021.04.042
- Guo Y, Logan HL, Glueck DH, et al. Selecting a sample size for studies with repeated
 measures. BMC Med Res Methodol. 2013;13: 1–8. doi:10.1186/1471-2288-13100/FIGURES/3
- Hartley GE, Edwards ESJ, Aui PM, et al. Rapid generation of durable B cell memory to
 SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci
 Immunol. 2020;5. doi:10.1126/SCIIMMUNOL.ABF8891
- Peng P, Deng H, Li Z, et al. Distinct immune responses in the early phase to natural
 SARS-CoV-2 infection or vaccination. J Med Virol. 2022;94: 5691–5701.
 doi:10.1002/JMV.28034
- Z3. Li C, Yue L, Ju Y, et al. Serum Proteomic Analysis for New Types of Long-Term
 Persistent COVID-19 Patients in Wuhan. Microbiol Spectr. 2022;10.
 doi:10.1128/SPECTRUM.01270-22
- Pedersen AB, Mikkelsen EM, Cronin-Fenton D, et al. Missing data and multiple
 imputation in clinical epidemiological research. Clin Epidemiol. 2017;9: 157.
 doi:10.2147/CLEP.S129785
- 75525.Hodcroft E. Overview of variants in countries: Malaysia. 2023 [cited 20 December7562023]. Available: https://covariants.org/per-country?country=Malaysia
- 757
- 758

759 List of figures

- 760
- **Figure 1.** Schedule of longitudinal blood sampling collection for up to 12 months and the
- 762 cross-sectional PBMCs sampling period during the expected waning antibody phases.
- 763

- 764 Figure 2. Overall LONGTONG-SARS2 study design of laboratory analysis comprising of i)
- 765 serology monitoring, ii) B- and T- memory cell functionality, iii) B lymphocyte population
- 766 counting, iv) cytokine profiling, and v) proteomic profiling.
- 767
- 768 **Figure 3.** Flow chart of group stratification changes from initial study groupings to revised
- study groupings to accommodate the cross-exposures in the participants immune response.

BNT162b2 vaccination group (VAC)



COVID-19 infected group (COV)











